We are live on ! Find out more
BBH icon

VanEck Biotech ETF

126 hedge funds and large institutions have $171M invested in VanEck Biotech ETF in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 33 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 12

7% more funds holding

Funds holding: 118126 (+8)

5% more capital invested

Capital invested by funds: $163M → $171M (+$8.32M)

2.41% more ownership

Funds ownership: 28.03%30.44% (+2.4%)

12% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 33

68% less call options, than puts

Call options by funds: $627K | Put options by funds: $1.95M

Holders
126
Holders Change
+8
Holders Change %
+6.78%
% of All Funds
1.94%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
21
Increased
29
Reduced
33
Closed
12
Calls
$627K
Puts
$1.95M
Net Calls
-$1.32M
Net Calls Change
-$862K

BBH Hedge Fund Activity: Q4 2021 in Review

126 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2021, worth a combined $171M — up 5.1% from $163M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new BBH positions and 12 closed out — a net gain of 9 holders — while 29 added to existing stakes and 33 trimmed.

The largest buyer was Bank of America, adding an estimated $17M. The largest seller was Stifel Financial, cutting an estimated $2.49M.

  • 126 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2021, up from 118 in Q3 2021.
  • Funds reported $171M of VanEck Biotech ETF stock for Q4 2021, up 5.1% quarter-over-quarter.
  • 21 funds opened new VanEck Biotech ETF positions in Q4 2021 and 12 closed out, a net change of +9 holders.
  • The largest VanEck Biotech ETF buyer in Q4 2021 was Bank of America, an estimated $17M added.
  • The largest VanEck Biotech ETF seller in Q4 2021 was Stifel Financial, an estimated $2.49M sold.

Based on aggregated 13F filings for Q4 2021.